Pentamidine Inhibits Ovarian Cancer Cell Proliferation and Migration by Maintaining Stability of PTEN in vitro

References

• StewartC, RalyeaC, LockwoodS. Ovarian cancer: an integrated review. Semin Oncol Nurs. 2019;35(2):151–156. doi:10.1016/j.soncn.2019.02.00130867104
   PubMed Web of Science ®Google Scholar
• WebbPM, JordanSJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41:3–14. doi:10.1016/j.bpobgyn.2016.08.00627743768
   PubMed Web of Science ®Google Scholar
• ZhouXJ, WuJ, ShiL, et al. PTEN expression is upregulated by a RNA-binding protein RBM38 via enhancing its mRNA stability in breast cancer. J Exp Clin Cancer Res. 2017;36(1):149. doi:10.1186/s13046-017-0620-329052531
   PubMed Web of Science ®Google Scholar
• QiY, LiuJ, ChaoJ, et al. PTEN suppresses epithelial-mesenchymal transition and cancer stem cell activity by downregulating Abi1. Sci Rep. 2020;10(1):12685. doi:10.1038/s41598-020-69698-132728066
   PubMed Web of Science ®Google Scholar
• WuH, WangK, LiuW, HaoQ. PTEN overexpression improves cisplatin-resistance of human ovarian cancer cells through upregulating KRT10 expression. Biochem Biophys Res Commun. 2014;444(2):141–146. doi:10.1016/j.bbrc.2014.01.01424434152
   PubMed Web of Science ®Google Scholar
• NeroC, CiccaroneF, PietragallaA, ScambiaG. PTEN and gynecological cancers. Cancers (Basel). 2019;11(10):1458. doi:10.3390/cancers11101458
   Web of Science ®Google Scholar
• LiuL, WangF, TongY, LiLF, LiuY, GaoWQ. Pentamidine inhibits prostate cancer progression via selectively inducing mitochondrial DNA depletion and dysfunction. Cell Prolif. 2020;53(1):e12718. doi:10.1111/cpr.1271831721355
   PubMed Web of Science ®Google Scholar
• PearsonRD, HewlettEL. Pentamidine for the treatment of Pneumocystis carinii pneumonia and other protozoal diseases. Ann Intern Med. 1985;103(5):782–786. doi:10.7326/0003-4819-103-5-7823901852
   PubMed Web of Science ®Google Scholar
• ArmstrongD, BernardE. Aerosol pentamidine. Ann Intern Med. 1988;109(11):852–854. doi:10.7326/0003-4819-109-11-8523056163
   PubMed Web of Science ®Google Scholar
• BrayPG, BarrettMP, WardSA, de KoningHP. Pentamidine uptake and resistance in pathogenic protozoa: past, present and future. Trends Parasitol. 2003;19(5):232–239. doi:10.1016/S1471-4922(03)00069-212763430
   PubMed Web of Science ®Google Scholar
• DiroE, RitmeijerK, BoelaertM, et al. Use of pentamidine as secondary prophylaxis to prevent visceral leishmaniasis relapse in HIV infected patients, the First Twelve Months of a Prospective Cohort Study. PLoS Negl Trop Dis. 2015;9(10):e0004087. doi:10.1371/journal.pntd.000408726431253
   PubMed Web of Science ®Google Scholar
• JungHJ, SuhSI, SuhMH, BaekWK, ParkJW. Pentamidine reduces expression of hypoxia-inducible factor-1alpha in DU145 and MDA-MB-231 cancer cells. Cancer Lett. 2011;303(1):39–46. doi:10.1016/j.canlet.2011.01.00821316841
   PubMed Web of Science ®Google Scholar
• ChowTY, Alaoui-JamaliMA, YehC, YuenL, GrillerD. The DNA double-stranded break repair protein endo-exonuclease as a therapeutic target for cancer. Mol Cancer Ther. 2004;3(8):911–919.15299074
   PubMed Web of Science ®Google Scholar
• SmithJ, StewartBJ, GlaysherS, et al. The effect of pentamidine on melanoma ex vivo. Anticancer Drugs. 2010;21(2):181–185. doi:10.1097/CAD.0b013e3283340cee19966562
   PubMed Web of Science ®Google Scholar
• PathakMK, DhawanD, LindnerDJ, BordenEC, FarverC, YiT. Pentamidine is an inhibitor of PRL phosphatases with anticancer activity. Mol Cancer Ther. 2002;1(14):1255–1264.12516958
   PubMed Web of Science ®Google Scholar
• WangH, QuahSY, DongJM, ManserE, TangJP, ZengQ. PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition. Cancer Res. 2007;67(7):2922–2926. doi:10.1158/0008-5472.CAN-06-359817409395
   PubMed Web of Science ®Google Scholar
• PerumalE, So YounK, SunS, et al. PTEN inactivation induces epithelial-mesenchymal transition and metastasis by intranuclear translocation of beta-catenin and snail/slug in non-small cell lung carcinoma cells. Lung Cancer. 2019;130:25–34. doi:10.1016/j.lungcan.2019.01.01330885348
   PubMed Web of Science ®Google Scholar
• HerS, CuiL, BristowRG, AllenC. Dual action enhancement of gold nanoparticle radiosensitization by pentamidine in triple negative breast cancer. Radiat Res. 2016;185(5):549–562. doi:10.1667/RR14315.127135970
   PubMed Web of Science ®Google Scholar
• VarkevisserR, HoutmanMJ, LinderT, et al. Structure-activity relationships of pentamidine-affected ion channel trafficking and dofetilide mediated rescue. Br J Pharmacol. 2013;169(6):1322–1334. doi:10.1111/bph.1220823586323
   PubMed Web of Science ®Google Scholar
• DengL, MengT, ChenL, WeiW, WangP. The role of ubiquitination in tumorigenesis and targeted drug discovery. Signal Transduct Target Ther. 2020;5(1):11.32296023
   PubMed Web of Science ®Google Scholar
• YuanL, LvY, LiH, et al. Deubiquitylase OTUD3 regulates PTEN stability and suppresses tumorigenesis. Nat Cell Biol. 2015;17(9):1169–1181. doi:10.1038/ncb321826280536
   PubMed Web of Science ®Google Scholar
• WorbyCA, DixonJE. Pten. Annu Rev Biochem. 2014;83:641–669. doi:10.1146/annurev-biochem-082411-11390724905788
   PubMed Web of Science ®Google Scholar
• XiaQ, AliS, LiuL, et al. Role of ubiquitination in PTEN cellular homeostasis and its implications in GB drug resistance. Front Oncol. 2020;10:1569. doi:10.3389/fonc.2020.0156932984016
   PubMed Web of Science ®Google Scholar
• LeeYR, ChenM, PandolfiPP. The functions and regulation of the PTEN tumour suppressor: new modes and prospects. Nat Rev Mol Cell Biol. 2018;19(9):547–562. doi:10.1038/s41580-018-0015-029858604
   PubMed Web of Science ®Google Scholar
• TrotmanLC, WangX, AlimontiA, et al. Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell. 2007;128(1):141–156. doi:10.1016/j.cell.2006.11.04017218261
   PubMed Web of Science ®Google Scholar
• LeeMS, JeongMH, LeeHW, et al. PI3K/AKT activation induces PTEN ubiquitination and destabilization accelerating tumourigenesis. Nat Commun. 2015;6:7769. doi:10.1038/ncomms876926183061
   PubMed Web of Science ®Google Scholar
• SelvendiranK, TongL, VishwanathS, et al. EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression. J Biol Chem. 2007;282(39):28609–28618. doi:10.1074/jbc.M70379620017684018
   PubMed Web of Science ®Google Scholar
• MarkmanM, HowellSB, LucasWE, PfeifleCE, GreenMR. Combination intraperitoneal chemotherapy with cisplatin, cytarabine, and doxorubicin for refractory ovarian carcinoma and other malignancies principally confined to the peritoneal cavity. J Clin Oncol. 1984;2(12):1321–1326. doi:10.1200/JCO.1984.2.12.13216542584
   PubMed Web of Science ®Google Scholar
• CassinelliG, ZucoV, GattiL, et al. Targeting the Akt kinase to modulate survival, invasiveness and drug resistance of cancer cells. Curr Med Chem. 2013;20(15):1923–1945. doi:10.2174/0929867311320999010623410153
   PubMed Web of Science ®Google Scholar
• HouR, ZhangJ, YinT, et al. Upregulation of PTEN by peroxynitrite contributes to cytokine-induced apoptosis in pancreatic beta-cells. Apoptosis. 2010;15(8):877–886. doi:10.1007/s10495-010-0510-z20464496
   PubMed Web of Science ®Google Scholar
• KeniryM, ParsonsR. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene. 2008;27(41):5477–5485. doi:10.1038/onc.2008.24818794882
   PubMed Web of Science ®Google Scholar
• YanX, FraserM, QiuQ, TsangBK. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner. Gynecol Oncol. 2006;102(2):348–355. doi:10.1016/j.ygyno.2005.12.03316545436
   PubMed Web of Science ®Google Scholar